铂-话题@MedSci - williamhill asia

#铂#

382篇内容 | 4304人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1737803, encodeId=e3291e378033f, content=<a href='/topic/show?id=292f965e5b5' target=_blank style='color:#2F92EE;'>#铂#</a>, objectTitle=Clin Cancer Res：西地尼布联合奥拉帕利治疗晚期铂耐药卵巢癌的疗效, objectType=article, longId=734952, objectId=a303e34952f4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a303e34952f4, replyNumber=0, likeNumber=94, createdTime=2023-05-16, rootId=0, userName=ms3153534357578991, userId=ca4034296500, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a303e34952f4, moduleTitle=Clin Cancer Res：西地尼布联合奥拉帕利治疗晚期铂耐药卵巢癌的疗效, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=a303e34952f4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1737806, encodeId=9efb1e37806ea, content=<a href='/topic/show?id=292f965e5b5' target=_blank style='color:#2F92EE;'>#铂#</a>, objectTitle=使用奥沙利铂时，这几个要点你必须知道！, objectType=article, longId=737700, objectId=bf5ce37700dc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bf5ce37700dc, replyNumber=0, likeNumber=84, createdTime=2023-01-03, rootId=0, userName=ms3153534357578991, userId=ca4034296500, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bf5ce37700dc, moduleTitle=使用奥沙利铂时，这几个要点你必须知道！, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=bf5ce37700dc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1737800, encodeId=a1df1e378000a, content=<a href='/topic/show?id=292f965e5b5' target=_blank style='color:#2F92EE;'>#铂#</a>, objectTitle= JCO：减量不减效？辅助治疗II/III 期结肠癌，3 个月奥沙利铂+6个月FU并不弱于6个月奥沙利铂+6个月FU！, objectType=article, longId=731245, objectId=ea67e3124570, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ea67e3124570, replyNumber=0, likeNumber=105, createdTime=2022-07-11, rootId=0, userName=ms3153534357578991, userId=ca4034296500, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ea67e3124570, moduleTitle= JCO：减量不减效？辅助治疗II/III 期结肠癌，3 个月奥沙利铂+6个月FU并不弱于6个月奥沙利铂+6个月FU！, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=ea67e3124570)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1737804, encodeId=25a81e3780462, content=<a href='/topic/show?id=292f965e5b5' target=_blank style='color:#2F92EE;'>#铂#</a>, objectTitle=中国之声：首个国产PD-1抑制剂联合双铂化疗新辅助治疗IIB-IIIB期NSCLC安全有效！| WCLC 2022速递, objectType=article, longId=735667, objectId=7b4ee35667af, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7b4ee35667af, replyNumber=0, likeNumber=108, createdTime=2023-06-10, rootId=0, userName=ms3153534357578991, userId=ca4034296500, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7b4ee35667af, moduleTitle=中国之声：首个国产PD-1抑制剂联合双铂化疗新辅助治疗IIB-IIIB期NSCLC安全有效！| WCLC 2022速递, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=7b4ee35667af)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1737801, encodeId=1fcd1e3780145, content=<a href='/topic/show?id=292f965e5b5' target=_blank style='color:#2F92EE;'>#铂#</a>, objectTitle=Ther Adv Med Oncol：洛铂新辅助治疗可改善三阴性乳腺癌患者预后, objectType=article, longId=731076, objectId=fee6e3107677, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fee6e3107677, replyNumber=0, likeNumber=130, createdTime=2022-10-12, rootId=0, userName=ms3153534357578991, userId=ca4034296500, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fee6e3107677, moduleTitle=Ther Adv Med Oncol：洛铂新辅助治疗可改善三阴性乳腺癌患者预后, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=fee6e3107677)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1737789, encodeId=84721e377895e, content=<a href='/topic/show?id=292f965e5b5' target=_blank style='color:#2F92EE;'>#铂#</a>, objectTitle=BMC Cancer：不可切除III期非小细胞肺癌（NSCLC）铂类放化疗进展后再给予铂类联合化疗可延长生存, objectType=article, longId=723595, objectId=19f4e2359542, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=19f4e2359542, replyNumber=0, likeNumber=80, createdTime=2022-05-08, rootId=0, userName=ms3153534357578991, userId=ca4034296500, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=19f4e2359542, moduleTitle=BMC Cancer：不可切除III期非小细胞肺癌（NSCLC）铂类放化疗进展后再给予铂类联合化疗可延长生存, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=19f4e2359542)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1737779, encodeId=57f81e37779bc, content=<a href='/topic/show?id=292f965e5b5' target=_blank style='color:#2F92EE;'>#铂#</a>, objectTitle=BMC Cancer：评估每周低剂量贝伐珠单抗联合方案治疗铂耐药卵巢癌患者的疗效, objectType=article, longId=299129, objectId=bdd0299129f0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bdd0299129f0, replyNumber=0, likeNumber=106, createdTime=2022-04-25, rootId=0, userName=ms3153534357578991, userId=ca4034296500, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bdd0299129f0, moduleTitle=BMC Cancer：评估每周低剂量贝伐珠单抗联合方案治疗铂耐药卵巢癌患者的疗效, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=bdd0299129f0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1737798, encodeId=ac2e1e37798ee, content=<a href='/topic/show?id=292f965e5b5' target=_blank style='color:#2F92EE;'>#铂#</a>, objectTitle=铂类药物不良反应怎么处理？一文讲清！, objectType=article, longId=730797, objectId=ae60e3079724, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ae60e3079724, replyNumber=0, likeNumber=100, createdTime=2022-11-28, rootId=0, userName=ms3153534357578991, userId=ca4034296500, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ae60e3079724, moduleTitle=铂类药物不良反应怎么处理？一文讲清！, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=ae60e3079724)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1737778, encodeId=95a81e3777854, content=<a href='/topic/show?id=292f965e5b5' target=_blank style='color:#2F92EE;'>#铂#</a>, objectTitle=Lancet Oncol：Sugemalimab联合含铂化疗一线治疗转移性非小细胞肺癌, objectType=article, longId=295668, objectId=63ef2956689c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=63ef2956689c, replyNumber=0, likeNumber=91, createdTime=2022-12-29, rootId=0, userName=ms3153534357578991, userId=ca4034296500, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=63ef2956689c, moduleTitle=Lancet Oncol：Sugemalimab联合含铂化疗一线治疗转移性非小细胞肺癌, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=63ef2956689c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1737793, encodeId=b14b1e37793e4, content=<a href='/topic/show?id=292f965e5b5' target=_blank style='color:#2F92EE;'>#铂#</a>, objectTitle=AACR重磅：帕博利珠单抗加卡培他滨和奥沙利铂及辅助帕博利珠单抗治疗可切除的胃和胃食管交界处（GC/GEJ）腺癌的II期试验, objectType=article, longId=723982, objectId=1388e239827e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1388e239827e, replyNumber=0, likeNumber=116, createdTime=2023-03-21, rootId=0, userName=ms3153534357578991, userId=ca4034296500, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1388e239827e, moduleTitle=AACR重磅：帕博利珠单抗加卡培他滨和奥沙利铂及辅助帕博利珠单抗治疗可切除的胃和胃食管交界处（GC/GEJ）腺癌的II期试验, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=1388e239827e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1737785, encodeId=cab41e377853a, content=<a href='/topic/show?id=292f965e5b5' target=_blank style='color:#2F92EE;'>#铂#</a>, objectTitle=J Clin Oncol：奥拉帕利±西地尼布 vs 化疗治疗复发性铂敏感性卵巢癌, objectType=article, longId=301138, objectId=85c9301138b8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=85c9301138b8, replyNumber=0, likeNumber=91, createdTime=2022-05-04, rootId=0, userName=ms3153534357578991, userId=ca4034296500, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=85c9301138b8, moduleTitle=J Clin Oncol：奥拉帕利±西地尼布 vs 化疗治疗复发性铂敏感性卵巢癌, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=85c9301138b8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1737805, encodeId=c6e01e37805b2, content=<a href='/topic/show?id=292f965e5b5' target=_blank style='color:#2F92EE;'>#铂#</a>, objectTitle=J Clin Oncol：吉非替尼 vs 吉非替尼+卡铂+培美曲塞治疗EGFR突变的非小细胞肺癌, objectType=article, longId=736047, objectId=95aee36047ae, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=95aee36047ae, replyNumber=0, likeNumber=116, createdTime=2022-09-24, rootId=0, userName=ms3153534357578991, userId=ca4034296500, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=95aee36047ae, moduleTitle=J Clin Oncol：吉非替尼 vs 吉非替尼+卡铂+培美曲塞治疗EGFR突变的非小细胞肺癌, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=95aee36047ae)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1737773, encodeId=48371e3777362, content=<a href='/topic/show?id=292f965e5b5' target=_blank style='color:#2F92EE;'>#铂#</a>, objectTitle=Transl Lung Cancer Res: 随机II期研究比较贝伐珠单抗联合不同铂类化疗方案治疗晚期非鳞状非小细胞肺癌(nsNSCLC)的疗效, objectType=article, longId=295291, objectId=de9929529101, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=de9929529101, replyNumber=0, likeNumber=115, createdTime=2022-04-16, rootId=0, userName=ms3153534357578991, userId=ca4034296500, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=de9929529101, moduleTitle=Transl Lung Cancer Res: 随机II期研究比较贝伐珠单抗联合不同铂类化疗方案治疗晚期非鳞状非小细胞肺癌(nsNSCLC)的疗效, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=de9929529101)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1737794, encodeId=e9b61e3779420, content=<a href='/topic/show?id=292f965e5b5' target=_blank style='color:#2F92EE;'>#铂#</a>, objectTitle=BMC Med：阿帕替尼+奥沙利铂+卡培他滨新辅助治疗局部晚期胃癌/胃食管交界处癌, objectType=article, longId=726038, objectId=a34fe2603805, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a34fe2603805, replyNumber=0, likeNumber=130, createdTime=2023-01-28, rootId=0, userName=ms3153534357578991, userId=ca4034296500, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a34fe2603805, moduleTitle=BMC Med：阿帕替尼+奥沙利铂+卡培他滨新辅助治疗局部晚期胃癌/胃食管交界处癌, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=a34fe2603805)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1737769, encodeId=0ed61e37769c9, content=<a href='/topic/show?id=292f965e5b5' target=_blank style='color:#2F92EE;'>#铂#</a>, objectTitle=Ann Oncol：TNBC患者标准新辅助化疗中加入卡铂联合或不联合veliparib（维拉帕利）的疗效和安全性, objectType=article, longId=295073, objectId=a9a02950e37b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a9a02950e37b, replyNumber=0, likeNumber=155, createdTime=2022-07-04, rootId=0, userName=ms3153534357578991, userId=ca4034296500, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a9a02950e37b, moduleTitle=Ann Oncol：TNBC患者标准新辅助化疗中加入卡铂联合或不联合veliparib（维拉帕利）的疗效和安全性, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=a9a02950e37b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1737802, encodeId=01e61e37802b2, content=<a href='/topic/show?id=292f965e5b5' target=_blank style='color:#2F92EE;'>#铂#</a>, objectTitle=Eur Urol Oncol：甲氨蝶呤、长春碱、阿霉素和顺铂在肌层浸润性膀胱癌患者中的安全性和有效性分析, objectType=article, longId=732583, objectId=f259e3258327, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f259e3258327, replyNumber=0, likeNumber=104, createdTime=2022-11-30, rootId=0, userName=ms3153534357578991, userId=ca4034296500, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f259e3258327, moduleTitle=Eur Urol Oncol：甲氨蝶呤、长春碱、阿霉素和顺铂在肌层浸润性膀胱癌患者中的安全性和有效性分析, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=f259e3258327)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1737796, encodeId=1dd31e3779602, content=<a href='/topic/show?id=292f965e5b5' target=_blank style='color:#2F92EE;'>#铂#</a>, objectTitle=J Immunother Cancer：卡瑞利珠单抗联合法米替尼治疗铂类进展的晚期或转移性尿路上皮癌的疗效和安全性, objectType=article, longId=726649, objectId=3c23e2664918, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3c23e2664918, replyNumber=0, likeNumber=91, createdTime=2023-04-10, rootId=0, userName=ms3153534357578991, userId=ca4034296500, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3c23e2664918, moduleTitle=J Immunother Cancer：卡瑞利珠单抗联合法米替尼治疗铂类进展的晚期或转移性尿路上皮癌的疗效和安全性, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=3c23e2664918)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1737797, encodeId=d1671e37797d6, content=<a href='/topic/show?id=292f965e5b5' target=_blank style='color:#2F92EE;'>#铂#</a>, objectTitle=JCO：ACHIEVE研究最终结果：III期结肠癌奥沙利铂为基础化疗辅助治疗3个月对比6个月的疗效和安全性, objectType=article, longId=727505, objectId=e820e275056e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e820e275056e, replyNumber=0, likeNumber=106, createdTime=2022-06-09, rootId=0, userName=ms3153534357578991, userId=ca4034296500, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e820e275056e, moduleTitle=JCO：ACHIEVE研究最终结果：III期结肠癌奥沙利铂为基础化疗辅助治疗3个月对比6个月的疗效和安全性, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=e820e275056e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1737791, encodeId=e3751e3779133, content=<a href='/topic/show?id=292f965e5b5' target=_blank style='color:#2F92EE;'>#铂#</a>, objectTitle=AACR 2022：围手术期帕博利珠单抗联合卡培他滨和奥沙利铂及辅助帕博利珠单抗治疗可切除胃和胃食管结合部(GC/GEJ)腺癌的II期试验, objectType=article, longId=724028, objectId=b171e24028fa, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b171e24028fa, replyNumber=0, likeNumber=84, createdTime=2022-10-03, rootId=0, userName=ms3153534357578991, userId=ca4034296500, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b171e24028fa, moduleTitle=AACR 2022：围手术期帕博利珠单抗联合卡培他滨和奥沙利铂及辅助帕博利珠单抗治疗可切除胃和胃食管结合部(GC/GEJ)腺癌的II期试验, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=b171e24028fa)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1737775, encodeId=2a791e377756e, content=<a href='/topic/show?id=292f965e5b5' target=_blank style='color:#2F92EE;'>#铂#</a>, objectTitle=Clin Cancer Res：奥拉帕尼单药维持治疗亚洲铂敏感的复发性卵巢癌患者的疗效, objectType=article, longId=295320, objectId=cf6e295320e6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cf6e295320e6, replyNumber=0, likeNumber=100, createdTime=2022-12-24, rootId=0, userName=ms3153534357578991, userId=ca4034296500, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cf6e295320e6, moduleTitle=Clin Cancer Res：奥拉帕尼单药维持治疗亚洲铂敏感的复发性卵巢癌患者的疗效, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=cf6e295320e6)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] williamhill asia 话题小助手

铂

2020-05-29

ms3153534357578991 (审核中...)

前往app查看评论内容

#铂#

Clin Cancer Res：西地尼布联合奥拉帕利治疗晚期铂耐药卵巢癌的疗效

2023-05-16

ms3153534357578991 (审核中...)

前往app查看评论内容

#铂#

使用奥沙利铂时，这几个要点你必须知道！

2023-01-03

ms3153534357578991 (审核中...)

前往app查看评论内容

#铂#

JCO：减量不减效？辅助治疗II/III 期结肠癌，3 个月奥沙利铂+6个月FU并不弱于6个月奥沙利铂+6个月FU！

2022-07-11

ms3153534357578991 (审核中...)

前往app查看评论内容

#铂#

中国之声：首个国产PD-1抑制剂联合双铂化疗新辅助治疗IIB-IIIB期NSCLC安全有效！| WCLC 2022速递

2023-06-10

ms3153534357578991 (审核中...)

前往app查看评论内容

#铂#

Ther Adv Med Oncol：洛铂新辅助治疗可改善三阴性乳腺癌患者预后

2022-10-12

ms3153534357578991 (审核中...)

前往app查看评论内容

#铂#

BMC Cancer：不可切除III期非小细胞肺癌（NSCLC）铂类放化疗进展后再给予铂类联合化疗可延长生存

2022-05-08

ms3153534357578991 (审核中...)

前往app查看评论内容

#铂#

BMC Cancer：评估每周低剂量贝伐珠单抗联合方案治疗铂耐药卵巢癌患者的疗效

2022-04-25

ms3153534357578991 (审核中...)

前往app查看评论内容

#铂#

铂类药物不良反应怎么处理？一文讲清！

2022-11-28

ms3153534357578991 (审核中...)

前往app查看评论内容

#铂#

Lancet Oncol：Sugemalimab联合含铂化疗一线治疗转移性非小细胞肺癌

2022-12-29

ms3153534357578991 (审核中...)

前往app查看评论内容

#铂#

AACR重磅：帕博利珠单抗加卡培他滨和奥沙利铂及辅助帕博利珠单抗治疗可切除的胃和胃食管交界处（GC/GEJ）腺癌的II期试验

2023-03-21

ms3153534357578991 (审核中...)

前往app查看评论内容

#铂#

J Clin Oncol：奥拉帕利±西地尼布 vs 化疗治疗复发性铂敏感性卵巢癌

2022-05-04

ms3153534357578991 (审核中...)

前往app查看评论内容

#铂#

J Clin Oncol：吉非替尼 vs 吉非替尼+卡铂+培美曲塞治疗EGFR突变的非小细胞肺癌

2022-09-24

ms3153534357578991 (审核中...)

前往app查看评论内容

#铂#

Transl Lung Cancer Res: 随机II期研究比较贝伐珠单抗联合不同铂类化疗方案治疗晚期非鳞状非小细胞肺癌(nsNSCLC)的疗效

2022-04-16

ms3153534357578991 (审核中...)

前往app查看评论内容

#铂#

BMC Med：阿帕替尼+奥沙利铂+卡培他滨新辅助治疗局部晚期胃癌/胃食管交界处癌

2023-01-28

ms3153534357578991 (审核中...)

前往app查看评论内容

#铂#

Ann Oncol：TNBC患者标准新辅助化疗中加入卡铂联合或不联合veliparib（维拉帕利）的疗效和安全性

2022-07-04

ms3153534357578991 (审核中...)

前往app查看评论内容

#铂#

Eur Urol Oncol：甲氨蝶呤、长春碱、阿霉素和顺铂在肌层浸润性膀胱癌患者中的安全性和有效性分析

2022-11-30

ms3153534357578991 (审核中...)

前往app查看评论内容

#铂#

J Immunother Cancer：卡瑞利珠单抗联合法米替尼治疗铂类进展的晚期或转移性尿路上皮癌的疗效和安全性

2023-04-10

ms3153534357578991 (审核中...)

前往app查看评论内容

#铂#

JCO：ACHIEVE研究最终结果：III期结肠癌奥沙利铂为基础化疗辅助治疗3个月对比6个月的疗效和安全性

2022-06-09

ms3153534357578991 (审核中...)

前往app查看评论内容

#铂#

AACR 2022：围手术期帕博利珠单抗联合卡培他滨和奥沙利铂及辅助帕博利珠单抗治疗可切除胃和胃食管结合部(GC/GEJ)腺癌的II期试验

2022-10-03

ms3153534357578991 (审核中...)

前往app查看评论内容

#铂#

Clin Cancer Res：奥拉帕尼单药维持治疗亚洲铂敏感的复发性卵巢癌患者的疗效

2022-12-24

科室
- - 订阅+
  - 更多科室
工具
服务